Comparative Efficacy, Safety and Tolerability of Olanzapine and Blonanserin in Patients with Schizophrenia: A Parallel Group Study

1. https://www.who.int/ [homepage on the Internet]. Geneva: World Health Organisation; © 2019 WHO [9 April 2018; cited 2019 Dec 09]. Available from: https://www.who.int/news-room/fact-sheets/detail/schizophrenia#.Xd1kXqdYobg.google.Search in Google Scholar

2. Gururaj G, Varghese M, Benegal V et al. and NMHS collaborators group. National Mental Health Survey of India, 2015-16: Summary. Bengaluru, National Institute of Mental Health and Neuro Sciences, NIMHANS Publication 2016 (128).Search in Google Scholar

3. Gur S, Weizman S, Stubbs B et al. morbidity and medical resources utilization of patients with schizophrenia: A case-control community-based study. Psychiatry Res. 2018; 260: 177-181.10.1016/j.psychres.2017.11.04229202380Search in Google Scholar

4. Remington G, Addington D, Honer W et al. Guidelines for the Pharmacotherapy of Schizophrenia in Adults. Can J Psychiatry. 2017;62(9):604-616.10.1177/0706743717720448559325228703015Search in Google Scholar

5. Tateno A, Sakayori T, Kim WC et al. Comparison of dopamine D3 and D2 receptor occupancies by a single dose of blonanserin in healthy subjects: A positron emission tomography study with [11C]-(+)-PHNO. Int J Neuropsychopharmacology. 2018; 21(6):522-7.10.1093/ijnp/pyy004600742129346639Search in Google Scholar

6. Tenjin T, Miyamoto S, Ninomiya Y, et al. Profile of blonanserin for the treatment of schizophrenia. Neuropsychiatr Dis Treat. 2013; 9:587-594.10.2147/NDT.S34433367792923766647Search in Google Scholar

7. Stroup TS, Gray N. Management of common adverse effects of antipsychotic medications. World Psychiatry. 2018; 17(3): 341-356.10.1002/wps.20567612775030192094Search in Google Scholar

8. Lally J, MacCabe JH. Antipsychotic medication in schizophrenia: a review, Brit Med Bulletin, 2015; 114(1): 169-179.Search in Google Scholar

9. Remington G, Foussias G, Fervaha G, et al. Treating Negative Symptoms in Schizophrenia: an Update. Curr Treat Options Psychiatry, 2016; 3: 133-150.10.1007/s40501-016-0075-8490816927376016Search in Google Scholar

10. Ko YK, Soh MA, Kang SH, Lee JI. The prevalence of metabolic syndrome in schizophrenic patients using antipsychotics. Clin Psychopharmacol Neurosci. 2013; 11(2): 80-88.10.9758/cpn.2013.11.2.80376675924023552Search in Google Scholar

11. Kato Y, Umetsu R, Abe J, et al. Hyperglycemic adverse events following antipsychotic drug administration in spontaneous adverse event reports. J Pharm Health Care Sci 1, 2015; 1: 15. doi: 10.1186/s40780-015-0015-6. eCollection 2015.472874926819726Open DOISearch in Google Scholar

12. Kawabe K, Horiuchi F, Ueno SI. Blonanserin, a novel antipsychotic, is suitable for treating schizophrenia associated with hyperprolactinemia: a case series. Clin Neuropharmacol. 2013; 36(6): 239-41.10.1097/WNF.000000000000000624201238Search in Google Scholar

13. Tenjin T, Miyamoto S, Ninomiya Y, et al. Profile of blonanserin for the treatment of schizophrenia. Neuropsychiatr Dis Treat. 2013; 9: 587-594.10.2147/NDT.S34433Search in Google Scholar

14. Nordgaard J, Revsbech R, Sæbye D, Parnas J. Assessing the diagnostic validity of a structured psychiatric interview in a first-admission hospital sample. World Psychiatry. 2012; 11(3): 181-185.10.1002/j.2051-5545.2012.tb00128.xSearch in Google Scholar

15. Meyer JM. Pharmacotherapy of psychosis and Mania. In: Brunton LL, Chabner BA, Knollmann BC, (eds.); Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 12th ed. China: McGraw-Hill Medical, 2011, 421-31.Search in Google Scholar

16. http://cdn.neiglobal.com/content/pg/live/blonanserin.pdf [package Insert]. [cited 2019 Dec 12]. Available from: http://cdn.neiglobal.com/content/pg/live/blonanserin.pdfSearch in Google Scholar

17. Zyprexa [package Insert]. Indianapolis (IN): Eli Lilly and Company, 2018. [cited 2019 Dec 12]. Available from: https://pi.lilly.com/us/zyprexa-pi.pdfSearch in Google Scholar

18. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep. 1962; 10: 792-812.Search in Google Scholar

19. Leon AC, Shear MK, Klerman GL et al. A comparison of sympyom determinants of patient and clinician global ratings in patients with panic disorder and depression. J Clin Psychopharmacol. 1993; 13(5): 327-31.10.1097/00004714-199310000-00005Search in Google Scholar

20. Ventura J, Nuechterlein KH, Subotnik KL et al. Symptom dimensions in recent-onset schizophrenia and mania: a principal components analysis of the 24-item Brief Psychiatric Rating Scale. Psychiatry Res. 2000; 97(2-3): 129-35.10.1016/S0165-1781(00)00228-6Search in Google Scholar

21. Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont). 2007; 4(7): 28-37.Search in Google Scholar

22. Upsala Monitoring Centre. The use of the WHO-UMC system for standardized case causality assessment [monograph on the internt]. Uppsala: Uppsala Monitoring Centre; 2005[cited 2008 Jul 7]. Availble from: http://www.who-umc.org/graphics/4409.Pdf.Search in Google Scholar

23. Brown MT, Bussell JK. Medication adherence: WHO cares?. Mayo Clin Proc. 2011; 86(4): 304-314. doi:10.4065/mcp.2010.0575Open DOISearch in Google Scholar

24. Gründer G, Heinze M, Cordes J et al. NeSSy Study Group. Effects of first-generation antipsychotics versus second-generation antipsychotics on quality of life in schizophrenia: a double-blind, randomised study. Lancet Psychiatry. 2016; 3(8): 717-729.10.1016/S2215-0366(16)00085-7Search in Google Scholar

25. Opler MGA, Yavorsky C, Daniel DG. Positive and Negative Syndrome Scale (PANSS) Training: Challenges, Solutions, and Future Directions. Innov Clin Neurosci. 2017; 14(11-12): 77-81.Search in Google Scholar

26. Woo YS, Yoon BH, Jeon BH, et al. Switching Antipsychotics to Blonanserin in Patients with Schizophrenia: An Open-label, Prospective, Multicenter Study. Clin Psychopharmacol Neurosci. 2019; 17(3): 423-431.10.9758/cpn.2019.17.3.423670509831352709Search in Google Scholar

27. Woo YS, Park JE, Kim DH, et al. Blonanserin Augmentation of Atypical Antipsychotics in Patients with Schizophrenia-Who Benefits from Blonanserin Augmentation?: An Open-Label, Prospective, Multicenter Study. Psychiatry Investig. 2016; 13(4): 458-467.10.4306/pi.2016.13.4.458496565827482249Search in Google Scholar

28. Huh L, Lee BJ. Comparison of long-term efficacy and safety of blonanserin treatment in individuals with first-episode and relapsed schizophrenia: a 3-year retrospective study, Psychiatry Clin Psychopharmacol, 2019; DOI: 10.1080/2475057 3.2019.1625184.Open DOISearch in Google Scholar

29. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care. 2003; 41(5): 582-92.10.1097/01.MLR.0000062554.74615.4C12719681Search in Google Scholar

30. Harvey, PD, Nakamura, H, Murasaki, M. Blonanserin versus haloperidol in Japanese patients with schizophrenia: A phase 3, 8-week, double-blind, multicenter, randomized controlled study. Neuropsychopharmacol Rep. 2019; 39: 173-182.10.1002/npr2.12057729226931041855Search in Google Scholar

31. Li H, Yao C, Shi J et al. Comparative study of the efficacy and safety between blonanserin and risperidone for the treatment of schizophrenia in Chinese patients: A double-blind, parallel-group multicenter randomized trial. J Psychiatric Res. 2015; 69:102-9.10.1016/j.jpsychires.2015.07.01526343601Search in Google Scholar

32. Kishi T, Matsuda Y, Matsunaga S et al. A randomized trial of aripiprazole vs blonanserin for the treatment of acute schizophrenia and related disorders. Neuropsychiatric Dis Treatment. 2016; 12: 3041.10.2147/NDT.S121588513540627932884Search in Google Scholar

33. Deepak TS, Raveesh BN, Parashivamurthy BM et al. Clinical Assessment of Weight Gain with Atypical Antipsychotics – Blonanserin vs Amisulpride. J Clin Diagn Res. 2015; 9(6): FC07–FC10.10.7860/JCDR/2015/13007.6066452552326266134Search in Google Scholar

34. Hirsch L, Yang J, Bresee L et al. Second-Generation Antipsychotics and Metabolic Side Effects: A Systematic Review of Population-Based Studies. Drug Safety 2017; 40(9): 771-781.10.1007/s40264-017-0543-028585153Search in Google Scholar

35. Upsala Monitoring Centre. The use of the WHO-UMC system for standardized case causality assessment [monograph on the internet]. Uppsala: Uppsala Monitoring Centre; 2005[cited 2019 Dec 11]. Availble from: http://www.who-umc.org/graphics/4409.Pdf.Search in Google Scholar

36. Yang J, Bahk WM, Cho HS, et al. Efficacy and tolerability of Blonanserin in the patients with schizophrenia: a randomized, double-blind, risperidone-compared trial. Clin Neuropharmacol. 2010; 33(4): 169-175.10.1097/WNF.0b013e3181dcda5020661022Search in Google Scholar

37. De Haan L, Van Amelsvoort T, Dingemans P, Linszen D. Risk factors for medication non-adherence in patients with first episode schizophrenia and related disorders; a prospective five year follow-up. Pharmacopsychiatry 2007; 40: 264-64.10.1055/s-2007-99214118030650Search in Google Scholar